Could a diabetes drug shield the liver? new trial tests empagliflozin in cirrhosis
NCT ID NCT07322237
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding empagliflozin (a diabetes drug) to standard carvedilol treatment can prevent liver decompensation events and death in 400 adults with cirrhosis and left ventricular diastolic dysfunction (stiff heart). Participants will receive either empagliflozin plus carvedilol or a placebo plus carvedilol for up to 2 years. The goal is to see if the combination reduces complications like bleeding, ascites, or kidney injury.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin and Carvedilol
What this could lead to
If it works, this combination could reduce the risk of serious liver complications and improve survival in people with cirrhosis and heart stiffness.
What could go wrong
This is a single-center Phase 4 trial, so results may not apply broadly. The drug may cause side effects like infections or low blood pressure, and the benefit over carvedilol alone is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
PGIMER Chandigarh
RECRUITINGChandigarh, 160012, India
Contact Phone: •••-•••-•••• Email: •••••@•••••